C4 Therapeutics Future Growth
Future criteria checks 2/6
C4 Therapeutics's earnings are forecast to decline at 1.9% per annum while its annual revenue is expected to grow at 35.4% per year. EPS is expected to grow by 12.3% per annum. Return on equity is forecast to be -555.8% in 3 years.
Key information
-1.9%
Earnings growth rate
12.3%
EPS growth rate
| Biotechs earnings growth | 27.7% |
| Revenue growth rate | 35.4% |
| Future return on equity | -555.8% |
| Analyst coverage | Good |
| Last updated | 07 Nov 2024 |
Recent future growth updates
Recent updates
C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout
Nov 06We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate
Oct 02
Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher
Aug 09C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up
Aug 03Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)
May 12C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched
Mar 01Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts
Feb 29C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Feb 24New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)
Nov 03Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week
May 14C4 Therapeutics wins FDA nod to study cancer candidate in solid tumors
Sep 29C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M
Aug 04Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00
May 10C4 Therapeutics: Poor Data Destroyed Preclinical Promise
May 04Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 21 | -163 | -144 | -139 | 5 |
| 12/31/2025 | 49 | -146 | -135 | -81 | 6 |
| 12/31/2024 | 35 | -109 | -89 | -67 | 6 |
| 9/30/2024 | 34 | -105 | -72 | -71 | N/A |
| 6/30/2024 | 29 | -108 | -79 | -78 | N/A |
| 3/31/2024 | 20 | -126 | -93 | -92 | N/A |
| 12/31/2023 | 21 | -132 | -109 | -107 | N/A |
| 9/30/2023 | 20 | -135 | -115 | -112 | N/A |
| 6/30/2023 | 16 | -140 | -115 | -109 | N/A |
| 3/31/2023 | 27 | -131 | -118 | -112 | N/A |
| 12/31/2022 | 31 | -128 | -111 | -106 | N/A |
| 9/30/2022 | 48 | -107 | -107 | -102 | N/A |
| 6/30/2022 | 50 | -99 | -94 | -93 | N/A |
| 3/31/2022 | 46 | -95 | -90 | -89 | N/A |
| 12/31/2021 | 46 | -84 | -88 | -87 | N/A |
| 9/30/2021 | 34 | -80 | -84 | -83 | N/A |
| 6/30/2021 | 34 | -82 | -81 | -79 | N/A |
| 3/31/2021 | 34 | -73 | -76 | -76 | N/A |
| 12/31/2020 | 33 | -66 | -68 | -67 | N/A |
| 9/30/2020 | 33 | -67 | -56 | -56 | N/A |
| 6/30/2020 | 30 | -52 | -50 | -49 | N/A |
| 3/31/2020 | 24 | -47 | 1 | 2 | N/A |
| 12/31/2019 | 21 | -43 | 54 | 56 | N/A |
| 12/31/2018 | 19 | -24 | -20 | -17 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CCCC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CCCC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CCCC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CCCC's revenue (35.4% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: CCCC's revenue (35.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CCCC is forecast to be unprofitable in 3 years.